Galenicum profiles its first launches for 2014
May 19, 2014
In December 2013 Galenicum obtained the approval of CODEM, the Spanish Drug Evaluation Committee, for almotriptan, and began the process for authorizing its sale once the patent is finalized. The main use of Almotriptan, a drug from the family of selective serotonin receptor agonists, is the treatment of migraine symptoms.
Additionally, in the month of January 2014 the company applied for dutasteride authorization from 17 European Union countries. The applications for approval for this drug, which is used to treat benign prostatic hyperplasia (BPH), have been filed in Spain, France, Germany, Italy, Portugal, Bulgaria, Croatia, Hungary, Greece, Malta, Lithuania, Finland, Romania, Czech Republic, Slovakia, Latvia and Slovenia.